

Oren Glanz

Co-founder and CEO, Lempo Therapeutics

Oren Glanz is an accomplished Israeli biotech entrepreneur with over 25 years of experience founding and scaling innovative companies. As the founder and CEO of Lempo Therapeutics, Oren is leading a groundbreaking initiative to revolutionize treatment for severe diseases through proprietary gene-editing technology targeting the innate immune system.

Lempo Therapeutics is developing a first-in-class therapeutic approach for Pulmonary Arterial Hypertension (PAH), with promising applications for multiple severe conditions including Multiple Sclerosis. The company's patented platform technology represents a paradigm shift in immunomodulation therapy with potential to address previously untreatable diseases.

Throughout his distinguished career, Oren has successfully built and exited multiple ventures, including TeleKnowledge Group (acquired by MTS Telecom) and Olista Corp (acquired by Connectiva Systems). His entrepreneurial vision extends beyond traditional business success to creating meaningful social impact.

In 2009, Oren founded ByThePeople, a social enterprise dedicated to empowering professionals to navigate career transitions through entrepreneurial thinking. There, he developed the acclaimed RealSTART acceleration methodology, a framework for efficiently transforming ideas into market-ready businesses while minimizing resource expenditure.

For his contributions to business innovation and social entrepreneurship, Oren has received numerous accolades, including a special honor for social impact from Globes Magazine, finalist for the Schwab Foundation "Social Entrepreneur of the Year" award and inclusion among "The 100 Most Influential Individuals in Israel" by TheMarker magazine (2012)

Oren brings a unique dual perspective to Lempo Therapeutics as both CEO and patient. Living with multiple sclerosis and confined to a wheelchair, he has a personal stake in the company's mission to develop an innovative immune system modulation therapy. This firsthand experience with a target condition drives his commitment to creating effective treatments for previously untreatable diseases.